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Staphylococcus aureus is both an important pathogen and a human commensal. To explore this
ambivalent relationship between host and microbe, we analysed the memory humoral
response against IsdB, a protein involved in iron acquisition, in four healthy donors. Here we
show that in all donors a heavily biased use of two immunoglobulin heavy chain germlines
generated high affinity (pM) antibodies that neutralize the two IsdB NEAT domains,
IGHV4-39 for NEAT1 and IGHV1-69 for NEAT2. In contrast to the typical antibody/antigen
interactions, the binding is primarily driven by the germline-encoded hydrophobic CDRH-2
motifs of IGHV1-69 and IGHV4-39, with a binding mechanism nearly identical for each
antibody derived from different donors. Our results suggest that IGHV1-69 and IGHV4-39,
while part of the adaptive immune system, may have evolved under selection pressure to
encode a binding motif innately capable of recognizing and neutralizing a structurally
conserved protein domain involved in pathogen iron acquisition.
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S
taphylococcus aureus is a major human pathogen that can
cause significant morbidity and mortality with a wide range
of clinical manifestations1. These include bacteremia,
pneumonia and infective endocarditis as well as osteoarticular,
skin and soft tissue, and device-related infections1. The clinical
burden is further exacerbated by the increasing occurrence of
antibiotic resistance, in particular the raise of methicillin-resistant
strains (MRSA)2. At the same time S. aureus is a human
commensal that is carried persistently (20–30%) or transiently
(Z50%) on the skin and in the nares of the general population1,
with the majority of individuals never experiencing an overt
infection episode. This remarkable commensal relationship, likely
of evolutionary origins, affords the opportunity to study the
immune response to a bacterial pathogen to which humans are
exposed on a continuous or recurrent basis over their lifetime.
To explore the role of the immune response in this host/
microbe interaction, we focused our attention on the mechanism
used by S. aureus to obtain the iron necessary for colonization
and pathogenesis3. S. aureus steals iron from haemoglobin, the
most abundant iron source within vertebrates, through the
concerted activity of the proteins in the iron-regulated surface
determinant (Isd) locus4. IsdB in particular, a surface-exposed
protein covalently anchored to the cell wall5, functions as a
central component of this pathway by removing heme from
haemoglobin and transferring it to other Isd proteins, which in
turn import and degrade it to release iron in the bacterial
cytoplasm4. IsdB contains two structurally conserved NEAT
(NEAr iron Transporter) domains than bind haemoglobin and
heme, respectively6–9. NEAT domains represent a structurally
conserved heme-binding protein fold encoded in the genomes
of several other Gram-positive human pathogens such as
Bacillus anthracis, Streptococcus pyogenes, Clostridium perfringens
and Listeria monocytogenes10,11. Importantly, S. aureus strains
lacking IsdB or with IsdB mutants unable to bind haemoglobin,
display a reduction in virulence in animal models of
staphylococcal infection6,12. It was also previously shown that a
recombinant anti-IsdB antibody was able to confer protection
against S. aureus infections in animal models13.
High-serum titres against lsdB, as well as other S. aureus
proteins, are readily observed in healthy adults14. While their
biological significance and possible role in protection against
infection remains to be elucidated, it has been shown that serum
titres against IsdB are elevated during infection15,16. Therefore, to
gain a better understanding of the functionality of these
antibodies and to explore the relationship between the human
immune system and the commensal pathogen S. aureus, we used
single-B cell cloning, phage display libraries, high-throughput
sequencing and epitope mapping17, structural and mutagenesis
methodologies to characterize in detail the humoral immune
response to the staphylococcal protein IsdB.
Results
Persistence of IsdB-reactive memory B cells. We first deter-
mined the presence of IsdB-reactive B cells in blood samples
collected from a donor (D3) at months 1, 3 and 15 using flow
cytometry (FACS), single-cell cloning (Supplementary Fig. 1) and
high-throughput sequencing techniques. By FACS, we observed
the persistence of a distinct IsdB-reactive memory B cell
population (B0.06%) within the IgM negative peripheral
memory compartment (Fig. 1a). The majority of the IsdB-reactive
memory B cells collected at three different time points expressed
clonally related B cell receptor (BCR) transcripts: 25 of the 31
unique IsdB-reactive clusters obtained from this donor contained
sibling transcripts isolated from at least two different time points
(Fig. 1b). Longitudinal lineage analysis of the heavy chain variable
region of these clusters indicates that the immune system
maintains a repertoire of continually evolving antibodies against
IsdB, presumably as a consequence of steady or intermittent
exposure to low levels of antigen due to the commensal rela-
tionship between humans and S. aureus (Supplementary Fig. 2).
Molecular characterization of the anti IsdB antibodies. To
investigate the nature of the interaction of these related antibodies
with their target antigens we cloned the heavy and light chain
BCR transcripts from single IsdB-reactive IgM CD19þ
CD27þ memory B cells obtained from the peripheral blood of
four healthy donors with high-antibody titre to IsdB (D1-4)
(Supplementary Figs 1 and 3). Overall, 75 unique antibodies
representing 438 single-cell BCR transcripts were confirmed to
bind both recombinant IsdB as well as IsdB on the surface of
iron-starved S. aureus cells. Next, we determined their epitope
binning, epitope mapping, affinity and ability to block
haemoglobin binding to IsdB (Fig. 1c; Supplementary Data 1 and
Supplementary Figs 4–7). We found the majority of the anti-
bodies to be directed against epitopes on the conserved core of
IsdB (NEAT1–Linker–NEAT2) (Fig. 1c; Supplementary Fig. 8a)
with two prominent sets of antibodies (bins C and P) that block
haemoglobin binding to IsdB, targeting NEAT1 and NEAT2,
respectively. Antibodies belonging to both sets are found in all
four donors (Fig. 1c; Supplementary Data 1). Surprisingly, among
the antibodies that bind NEAT1, there is a strong bias (7 out of 12
antibodies) towards using the immunoglobulin heavy chain
variable gene (IGHV) 4-39 and immunoglobulin kappa light
chain variable gene (IGKV) (Supplementary Fig. 9a), whereas the
antibodies that bind NEAT2 are invariably derived from the
IGHV1-69 germline and IGKV light chains (Supplementary
Fig. 9b), irrespective of the donor of origin. Remarkably, we
found several of these antibodies to have affinities in the single
digit pico-molar range at 37 C (Fig. 2e; Supplementary Fig. 6).
Characterization of IGHV1-69-derived NEAT2 binders (Bin P).
To elucidate the binding mechanism between the IGHV1-69-
derived antibodies and NEAT2, we determined two crystal
structures of Fabs from two different donors in complex with
NEAT2 (Fig. 2a and Table 1; Supplementary Fig. 10a,b). Both
structures, denoted by D2-06-N2 (3.22Å) and D4-30-N2
(3.21 Å), surprisingly exhibited a nearly identical NEAT2 binding
mode (Fig. 2a), with the heavy chain variable domain (VH),
particularly complementary determining region (CDR)-H2,
dominating the interaction in both structures (Fig. 2b).
Specifically, the V-gene encoded CDR-H1 and CDR-H2 con-
tribute 64% of the total buried surface area (BSA) for both
structures (Fig. 2d). This heavy reliance on CDR-H1 and CDR-
H2 is unusual for antibody/antigen interactions as highly diverse,
VDJ recombination-generated CDR-H3s are typically considered
to be the most important CDR for antigen binding18,19. The
CDR-H2s of the Fabs engage the NEAT2 domain in two major
modes. First, the b7-turn-b8 of NEAT2 slides into a groove at the
interface of heavy and light chain variable regions, forming major
contacts with the stem of the CDR-H2 loop. Second, F54 (Kabat
numbering) of CDR-H2 protrudes into the hydrophobic heme
pocket of NEAT2, made up of M362, M363 and F366 in the a-
helix 1, V435 on the b7 and Y440 and Y444 on the b8 of IsdB
(Fig. 2b,c). While this group of NEAT2 binding antibodies was
initially found to block haemoglobin binding to IsdB, which likely
occurs by steric hindrance as IsdB NEAT1 and NEAT2 are
proposed to be spatially adjacent to each other based on their
homology to the solved crystal structure of haemoglobin bound
to IsdH NEAT2–linker–NEAT3 (ref. 20), the structural data
reveals a second very effective way to block the activity of IsdB as
antibody binding to the heme pocket precludes the possibility of
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concurrent heme binding9. Given the highly conserved nature of
S. aureus NEAT2, particularly at the binding interface
(Supplementary Fig. 8), we predict that these IGHV1-69-
derived antibodies will be able to recognize and neutralize IsdB
encoded by the vast majority if not all S. aureus strains (4,112
strains analysed in this study).
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Figure 1 | Characterization of anti-IsdB antibodies in the human memory B cell repertoire. (a) A persistent population of IsdBþ memory B cells from the
peripheral blood mononuclear cells (PBMC) of a donor (D3) was observed over a 15-month period. By FACS, B0.06% of the IgM CD19þ CD27þ
memory B cells in the total memory B cell repertoire of this donor bind IsdB. (b) Most of the cloned BCR transcripts of the IsdBþ memory B cells collected
at month 1, 3 and 15 are clonally related. BCR sequences from single-cell cloning of IsdBþ memory B cells were clustered based on heavy chain V-gene
usage and CDR-H3 sequences. In total, we identified 31 unique clusters from donor D3 over the three collection time points. The Venn diagram shows that
sibling clones within a cluster can be isolated at multiple time points. (c) Two distinct sets (bin C and bin P) of function-blocking antibodies specifically
target NEAT1 and NEAT2, respectively. Single-cell cloning was performed at three different time points for donor D3 and one time each for donors D1, D2,
and D4. In total, 75 unique antibodies targeting IsdB were identified and characterized. Shown here are the results of a comprehensive epitope binning
analysis of 67 antibodies. Each reformatted clone is shown as a box and coloured according to its VH germline usage. The height of the box indicates the
number of clustered BCR transcripts represented for each reformatted clone. There are in total 9, 34, 327, and 68 anti-IsdB single-cell BCR transcripts for
D1, D2, D3 and D4, respectively. Each column of clones represents an epitope bin and this is overlaid on top of a linear representation of the IsdB molecule
with NEAT1 in orange, and NEAT2 in blue. Clones that are able to fully block haemoglobin binding are outlined with a red box.
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Figure 2 | Germline-encoded binding of IGHV1-69 to the NEAT2 domain of IsdB. (a) Crystal structure of IGHV1-69-derived Fabs from two donors
(D2-06-N2 and D4-30-N2) in complex with NEAT2. The Fabs of D2-06-N2 and D4-30-N2 show a near identical binding mechanism to NEAT2 as
evidenced by the superimposed structures. To facilitate the crystallization process, a sandwiching Fab from an antibody (D3–13) that binds NEAT2 at a
non-overlapping epitope was used. For clarity, the sandwiching Fab is removed from the figure, but is included in the Supplementary Data (Supplementary
Fig. 10a,b). (b) Both IGHV1-69-derived antibodies use the conserved F54 on CDR-H2 to interact with the heme-binding pocket of NEAT2. The stem of the
CDR-H2 loop also mediates major contacts with the b7-turn-b8 loop of NEAT2. (c) The heme pocket residues of NEAT2 which interact with the conserved
F54 on CDR-H2 are highlighted in the complex with D2-06-N2. They are M362, M363 and F366 in a-helix 1, V435 on the b-strand 7, and Y440 and Y444
on the b-strand 8. (d) CDR-H2 dominates the interaction in terms of BSA in both structures. Structural analysis shows that 75–80% of the BSA is
attributed to the heavy chain, and 20–25% to the light chain. In particular, the CDR-H2 contributes 41 and 49% of total BSA for the respective structures.
(e) Mutational analysis confirms the structural data and demonstrates that all IGHV1-69-derived antibodies in this set bind NEAT2 with a similar
mechanism. The KD for all antibodies in this set and their respective F54A variants against IsdB NEAT2 were determined by SPR-based biosensor assays at
37 C (KD range, nZ2). Antibody binding to NEAT2 variants of V435R (heme-binding pocket) and D390A/K436A/T437A (b7-turn-b8 loop) was tested
by ELISA (percentage binding relative to binding to wild type IsdB, one representative set of results out of three independent experiments is shown). Clones
from each donor were reverted to VH germline sequence and tested for binding to NEAT2 by both ELISA and biosensor analysis, and ability to block
haemoglobin binding. N.D. stands for not determined.
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We next used mutagenesis to determine if the other eight
IGHV1-69-derived antibodies in this set bind IsdB in a similar
manner, as suggested by the fact that they all share the IGHV1-69
framework and a conserved F54 in CDR-H2. Figure 2e shows that
a single mutation at the surface-exposed F54 position (F54A)
resulted in 4100-fold loss in affinity for all of the antibodies,
highlighting that its importance for binding is shared by every
antibody in this set. To further substantiate the common binding
mode, we generated NEAT2 variants with mutations at the
binding interface residues. Mutations in the heme pocket
(V435R) and at the base of the b7-turn-b8 motif (D390A/
K436A/T437A; Fig. 2c) consistently disrupted binding to every
antibody in the NEAT2 binding set without affecting binding of
antibodies that also bind NEAT2 but belong to different epitope
bins (Fig. 2e). We observed slight differences in the extent to
which mutations at several NEAT2 residues impacted the binding
of the antibodies (Supplementary Fig. 11a,c), presumably due to
subtle differences in how the distinct CDR-H3 and CDR-L3 of
each antibody contribute to binding IsdB. Overall, the combina-
tion of structural and mutagenesis data indicates that IGHV1-69-
derived antibodies from four donors bind NEAT2 in similar
fashion by primarily using CDR-H2 germline residues.
Having established the prominent role of CDR-H2 in binding
NEAT2 of IsdB, we determined if these antibodies have other
commonalities by first examining the contribution of the
individual CDR-H3 and J-region residues based on the two
crystal structures and then by comparing the CDR-H3 amino
acid usage of the 10 isolated binders to that of IGHV1-69-derived
antibodies in memory repertoires of twelve healthy donors
(Supplementary Fig. 12). For the heavy chain, we did not observe
any common residue on CDR-H3 and JH that contributes
substantially to the binding to NEAT2. Sequence analysis of the
10 binders also did not reveal any particular preference in
immunoglobulin heavy chain joining segment (IGHJ) usage as
IGJH1, 3 and 4 were all used (Supplementary Data 1). There
seems to be a bias for charged residues (D, K or R) at position 95
and glycine at position 96, but both positions only have minor
contributions to the overall binding based on the structures
(Supplementary Fig. 12). As for the light chain, which overall
contributes only 20–24% to the binding surface, there is no
apparent preference for the IGKV or immunoglobulin kappa light
chain joining segment (IGKJ) usage based on the 10 binders.
Interestingly, the CDR-L3s of all the binders are 11 amino acids
long, likely resulting from a direct fusion of IGKV and IGKJ
genes. On the basis of the crystal structures, the two aromatic
residues at position 94 and 96, which form a distinct motif (F/W-
P-W/Y), are responsible for the majority of the CDR-L3
contribution to the binding. This motif was also found in
another three binders, and a similar X-P-X motif was also found
in four of the remaining five binders, suggesting a potential
preference for light chain having a specific pattern at position 94–
96 in pairing with IGHV1-69-derived heavy chain to bind
NEAT2.
Germline-reverted variants of IGHV1-69-derived antibodies.
The shared binding mode of the IGHV1-69-derived antibodies
led us to hypothesize that this germline has inherent potential to
recognize the NEAT2 domain of IsdB. This hypothesis was tested
by reverting the heavy chain V-gene region (framework 1 to
framework 3) of multiple clones from each donor to their
respective germline precursor sequences and testing their binding
to IsdB NEAT2 by ELISA and biosensor. While we observed
significant losses in monovalent affinity for all the germline-
reverted clones (4600 fold compared with the originally isolated
clones), all of them were still able to bind IsdB NEAT2 by ELISA
with four germline-reverted clones, D2-06-N2, D3-01-N2,
D3-05-N2 and D3-18-N2, having surprisingly high-monovalent
affinity (24 nM–60 nM) to NEAT2 (Fig. 2e). In contrast,
non-matured antibodies from naı¨ve B cells typically bind antigen
with high micro-molar affinity and binding can only be reliably
detected in avidity-driven assays21,22. This data further supports
the hypothesis that the IGHV1-69 germline possesses inherent
capability to bind IsdB NEAT2. Also, these germline-reverted
antibodies retain the ability to block haemoglobin binding
(Fig. 2e; Supplementary Fig. 7).
Allelic preference of IGHV1-69-derived antibodies. Moreover,
we determined that the binding of IGHV1-69-derived antibodies
to IsdB is strongly influenced by the allelic variation at position 50
(Fig. 3a). We found that the presence of R50, in contrast to G50
or A50 as in the antibodies described here, completely abolished
the binding (Fig. 3b,c), presumably due to the steric clash between
the extended side-chain of R50 and the IsdB b7-turn-b8 of
NEAT2 (ref. 23; Fig. 3d). Data from the 1000 Genomes Project
show that the R50 polymorphism, which abolishes NEAT2
binding, is present in 38% of the IGHV1-69 allele with a pre-
dicted homozygous rate of 14% in the general population24. This
raises the possibility that there is a population-level difference in
the ability to neutralize NEAT2-mediated heme-iron acquisition
and therefore different susceptibility to S. aureus infection25,26.
Characterization of IGHV4-39-derived NEAT1 binders (Bin C).
We also characterized a second class of antibodies that are
derived from IGHV4-39 and bind to the NEAT1 domain of IsdB.
We determined the crystal structure of the D4-10-N1 Fab in
complex with NEAT1 (3.17 Å; Fig. 4a and Table 1;
Supplementary Fig. 10c). The structure reveals that binding is
Table 1 | Data collection and refinement statistics (molecular
replacement).
D2-06-N2
5D1Q
D4-30-N2
5D1X
D4-10-N1
5D1Z
Data collection
Space group P 42 21 2 P 41 P 2 21 21
Cell dimensions
a, b, c (Å) 121.3, 121.3,
193.2
111.3, 111.3,
105.2
115.2, 147.1,
164.9
a, b, g () 90, 90, 90 90, 90, 90 90, 90, 90
Resolution (Å) 47.33–3.22 49.18–3.21 24.96–3.17
Rsym or Rmerge 9.6 (53.6) 11.1 (46.3) 15.6 (56.8)
I/sI 20.4 (3.4) 10.8 (1.97) 7.6 (1.95)
Completeness (%) 98.8 98.9 97.9
Redundancy 6.6 (6.6) 3.3 (3.1) 3.5 (3.4)
Refinement
Resolution (Å) 3.22 3.21 3.17
No. reflections 22,680 19,661 45,212
Rwork/Rfree 21.7/28.1 27.1/30.9 23.7/28.6
No. atoms
Protein 7,583 6,684 15,717
Ligand/ion — — —
Water — — —
B-factors
Protein 93.787 87.022 49.474
Ligand/ion — — —
Water — — —
R.m.s. deviations
Bond lengths (Å) 0.012 0.009 0.012
Bond angles () 1.697 1.465 1.539
One crystal used for each structure. *Values in parentheses are for highest-resolution shell.
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again dominated by the heavy chain, particularly by CDR-H2,
which contributes 45% of the BSA (Fig. 4b). Specifically,
D4-10-N1 utilizes CDR-H2 residues Y52 and F53 to interact with
residues Y165 of NEAT1, targeting the same binding region that
is responsible for the interaction between haemoglobin and
NEAT1 (ref. 6; Supplementary Fig. 13) and therefore providing a
mechanistic explanation on how antibodies in this group block
haemoglobin binding. Remarkably, CDR-H2 F53 protrudes into a
hydrophobic pocket of NEAT1 that is structurally homologous to
the heme pocket of NEAT2. Therefore this resembles the IGHV1-
69 CDR-H2 interaction with NEAT2 (Supplementary Fig. 14).
All antibodies in the NEAT1-binding group have a conserved
aromatic residue (Y or F) at positions 52 and 53, and lost binding
to NEAT1 when these residues were mutated to A (Fig. 4c).
Correspondingly, mutations of NEAT1 at residue Y165 abolished
binding for every antibody in this group without disrupting
the binding of antibodies that also bind NEAT1 but belong to
different epitope bins (Fig. 4c and Supplementary Fig. 11b,d).
Collectively, the structural and mutational data strongly suggest
that all of the antibodies in this set interact with NEAT1 in a
similar fashion. Similar to NEAT2, the sequence of NEAT1 is also
highly conserved (Supplementary Fig. 8), therefore we expect
these IGHV4-39-derived antibodies to be able to recognize and
neutralize IsdB encoded by the vast majority if not all S. aureus
strains.
Among the seven IGHV4-39-derived NEAT1 binders there are
no apparent preferences on the usage of IGKV germlines, IGKJ
and IGHJ regions (Supplementary Data 1). Analysis of the amino
acid usage in CDR-H3 (Supplementary Fig. 15) revealed a strong
underrepresentation of R at position 94, as S, T and K were used
instead. This may affect the typical salt-bridge connection
between R94 and D101, which structurally supports the
CDR-H3 loops. Four out of the seven binders are missing the
typical pairing of K/R94 and D101. In addition, we also observed
that P or G, which can alter the backbone conformation, are
preferred at position 95. Therefore it is plausible that even though
both residues do not mediate direct binding based on the crystal
structure, they could co-operate to uniquely orient the CDR-H3
residues in these IGHV4-39-derived NEAT1 binders. Charged
residues were also found preferentially at position 99 and 100
0 50 100
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Figure 3 | Allelic specificity of IGHV1-69-derived NEAT2 binders. (a) Amino acid differences among functional alleles of IGHV1-69. (b) The VH of clone
D2-06-N2 was germline-reverted to all alleles with amino acid differences, and tested for binding to IsdB by ELISA. All alleles with a G50R substitution lost
binding. ELISA data is an average of three independent experiments. Error bars are defined as s.d. (c.) Three individual variants (G50R, F54L and T56I) of
D2-06-N2 (IGHV1-69*01 germline-reverted) were generated and their binding to IsdB was tested. Only variant G50R showed significant loss of binding.
ELISA data is an average of three independent experiments. Error bars are defined as s.d. (d) Analysis of the structure illustrates how a change from G to R
(most frequent rotamer) at position 50 is expected to cause a steric clash in the binding to NEAT2.
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among the binders. However, both residues do not have any
direct contact with NEAT1 in the crystal structure of D4-10-N1.
The sequence/structure analysis did not reveal any common
contact residue among the CDR-H3s of the seven
IGHV4-39- IGKV-derived binders.
Germline-reverted variants of IGHV4-39-derived antibodies.
Given the prominent role of the IGHV4-39 germline-encoded
CDR-H2 in binding IsdB NEAT1, we next measured the
affinity of heavy chain V-gene germline-reverted (framework
1–framework 3) antibodies for all IGHV4-39 antibodies.
Remarkably, all IGHV4-39 germline-reverted antibodies exhib-
ited very high affinities (with KD values at 37 C in the single- to
triple-digit nanomolar range; Fig. 4c), supporting the idea that
the IGHV4-39 germline has intrinsic potential for recognizing
IsdB NEAT1. These germline-reverted antibodies can also block
a
c
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Figure 4 | Germline-encoded binding of IGHV4-39 to the NEAT1 domain of IsdB. (a) Crystal structure of an IGHV4-39-derived Fab (D4-10-N1) in
complex with NEAT1. The two aromatic resides (Y52 and F53) in CDR-H2 interact with the a-helix1 of NEAT1 which is normally involved in binding
haemoglobin. IGHV4-39 CDR-H2 F53 of Fab D4-10-N1 protrudes into a hydrophobic pocket of NEAT1, which is structurally homologous to the heme
binding pocket of NEAT2. Crystallization was facilitated by the use of a sandwiching Fab from an antibody (D3–19) that binds NEAT1 at a non-overlapping
epitope (bin H). For clarity, the sandwiching Fab is removed from the figure but is included in the Supplementary Data (Supplementary Fig. 10c). (b) CDR-
H2 dominates the interaction in terms of BSA. Structural analysis shows that 79% of the BSA is attributed to the heavy chain, and 21% to the light chain.
The CDR-H2 contributes about 45% of total BSA. (c) Mutational analysis confirms the structural data and demonstrates that all IGHVderived antibodies in
this set bind NEAT1 with a similar mechanism. The KD for all antibodies in this set was determined by SPR-based biosensor binding analysis to recombinant
full-length IsdB at 37 C (KD range, nZ2). The binding of antibody variants at positions 52 and 53 of CDR-H2 to wild type IsdB and the binding of antibodies
to NEAT1 variant Y165R (a-helix 1) were evaluated by ELISA (percentage binding relative to binding between original isolated antibodies and wild type IsdB,
one representative set of results out of three independent experiments is shown). Every clone was reverted to VH germline sequence and tested for binding
to NEAT1 by biosensor analysis and ability to block haemoglobin binding. ND stands for not determined.
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haemoglobin binding (Fig. 4c; Supplementary Fig. 7). This feature
appeared to be specific for IGHV4-39, as reverting
selected antibodies to two other highly homologous germlines23,
IGHV4-30*04 and IGHV4-61*01, resulted in significant loss
of binding for the antibodies evaluated (Fig. 5). Unlike the
IGHV1-69 NEAT2 binders, allelic variation did not appear to
affect the ability of IGHV4-39-derived clones to bind NEAT1
(ref. 23; Fig. 5).
IGHV4-39 encoded NEAT1 binders from naı¨ve B cells. To
expand the breadth of our findings we first tested serum samples
from 36 donors (including the original 4 donors) against the two
NEAT domains of IsdB and show that there are detectable titres
against both NEAT domains (Supplementary Fig. 16). Moreover,
these titres were reduced by pre-blocking the NEAT domains
with antibodies that bind the haemoglobin and heme-binding
sites, suggesting that antibodies that target the functional domains
of IsdB are present in the serum of all donors tested
(Supplementary Fig. 16).
Next, given that the majority of the IsdB NEAT domain
binding was primarily driven by germline-encoded CDR-H2, we
investigate if antibodies from naı¨ve B cells can recognize IsdB in a
similar manner as the one described above and asked if such
antibodies could be found in additional donors. Using individu-
ally barcoded IGHV4-39 specific primers, we selectively amplified
the IGHV4-39 variable heavy chain gene from the cDNA of
sorted CD19þ CD27 IgMþ naı¨ve B cells of 36 individuals;
this allowed us to unequivocally match binders with their
respective donors. A single-chain Fv (scFv) phage display library
was then constructed by pairing the individually barcoded
IGHV4-39 VH gene with the pooled naı¨ve IGKV families 1–4
genes from all donors (schematics are shown in Fig. 6a).
Sequencing of the starting phage library confirmed that the
heavy chain of more than 90% of the clones was encoded by
IGHV4-39, with minor contaminations from other IGHV4 family
members. After four rounds of panning against IsdB NEAT1
domains, the binding of 960 individual phage clones against IsdB
and its variants was evaluated by ELISA. About 90% of the clones
showed specific binding to full-length IsdB and IsdB NEAT1
domain. Sequence analysis determined that three of the phage
clones with unique CDR-H3 (D14-1, D15-1 and D16-1)
represented the majority of the binders (96%); this could be
due to their superior affinity as scFv’s (not determined) or to a
growth bias introduced through the phage amplification process.
Despite the presence of these three dominant clones, we were able
to isolate a total of 16 clones with unique CDR-H3 sequences
from 13 different donors (Supplementary Fig. 17).
The binding characteristics of the isolated clones were then
evaluated. Remarkably all the unique phage clones lost binding to
IsdB NEAT1 variant Y165R, suggesting that all the clones bind
the haemoglobin-binding pocket on NEAT1 (Supplementary
Fig. 17). Next, one clone from seven different donors was
randomly selected and reformatted as IgG (Fig. 6b and
Supplementary Fig. 18). Consistent with the phage binding
results, all seven reformatted IGHV4-39-derived antibodies
maintained the ability to recognize IsdB NEAT1 and all lost
binding to the IsdB Y165R variant as measured by Elisa
(Supplementary Fig. 18). We confirmed binding of these
antibodies to IsdB in a monovalent based biosensor assay at
37 C, while their Y52A/Y53A variants lost the ability to bind
IsdB (Supplementary Fig. 18). Overall, these results showed that
the naı¨ve IGHV4-39 clones isolated from the naı¨ve B cells of
13 additional donors bind IsdB NEAT1 in a manner similar and
consistent with the binding interaction described above for the
antibodies isolated from the memory B cells of four donors. This
further strengthens the suggestion that IGHV4-39 possesses
inherent affinity toward the NEAT1 domain of IsdB of S. aureus.
We next used the sequence information from these phage-
derived NEAT1 binders to further examine the immunoglobulin
gene use looking for any additional features that may be common
to all IGHV4-39-derived binders. First, the naı¨ve nature of these
phage binders allows DH gene usage to be more reliably
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Figure 5 | Germline and allelic specificity of IGHV4-39-derived NEAT1
binders. (a) Clone D4-10-N1 was reverted to all allelic variants with amino
acid differences relative to IGHV4-39*01. No differences in IsdB binding
were observed. Results shown are an average of three independent
experiments. Error bars are defined as s.d. (b) IGHV4-39*01 has high
sequence homology to IGHV4-30*04 and IGHV4-61*01 (they only differ by
six amino acids in the variable region), and they all have the critical Y52 and
Y53 residues in the CDR-H2. (c) The VH of four clones, one from each
donor, were reverted to both IGHV4-30*04 and IGHV4-61*01, and their
binding to IsdB was tested by ELISA. All IGHV4-30*01-derived variants
were unable to bind IsdB, while most of the IGHV4-61*01-derived variants
exhibited significantly loss of binding. ELISA data is an average of three
independent experiments. Error bars are defined as s.d.
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identified; we did not observe any preference for specific DH
genes (Supplementary Fig. 17). Meanwhile, similar to what was
observed for the NEAT1 binders isolated from memory B cells,
we identified a strong underrepresentation of R at position 94
(G, S and T are used instead), as 14 of 16 phage binders (88%) do
not have the typical salt-bridge pair of R94-D101. This is in
contrast to the starting library, where 77% of the phage clones
have R94 and D101 (Supplementary Fig. 19). In addition, the
remaining two clones possessing the R94-D101 pair have P at
position 95. This was also frequently observed in the memory
B-cell-derived binders (Supplementary Fig. 15). Besides position
94 and 95, there is no apparent preference for amino acid usage in
the CDR-H3 (Supplementary Fig. 19). Unexpectedly, IGHJ3 was
exclusively used for all of the phage isolated binders. This strong
bias of IGJH3 was not observed in our seven NEAT1 binders
isolated from memory B cells, as all IGHJ1-6 genes were used.
It is possible that this bias was introduced by displaying
antibodies as scFv or by an inherent bias of the phage selection
process. As for the light chain, IGKV3-20 was the most frequently
used variable kappa light chain (VK) germline in these binders
(11 out of 16), similar to what we observed from the memory B
cells-derived NEAT1 binders (3 out of 7).
Discussion
In this study, we characterized in detail the endogenous humoral
response in healthy individuals against IsdB, a prominent
molecule in the iron-acquisition pathway necessary for coloniza-
tion and pathogenesis of the commensal bacterium S. aureus.
We found that the human immune system maintains a sizable
repertoire of continually evolving IsdB-reactive memory B cells
by comparing the repertoire of a NEAT-2 binder over a
15-month period (Supplementary Fig. 2). For IsdB, high-serum
titres are representative of antibodies that bind to a variety of
epitopes on IsdB. Among them, we identified two prominent
sets of neutralizing antibodies that target the specific fold of the
highly conserved NEAT domains of IsdB with a dedicated, highly
specific V-gene response for each NEAT domain, IGHV4-39 for
NEAT1 and IGHV1-69 for NEAT2. Interestingly these neutraliz-
ing antibodies are not derived from the IGHV3 family which
encode antibodies targeted by the S. aureus virulence factor
Protein A27,28. These antibodies bind with very high affinity and
neutralize the activity of IsdB by occupying the structurally
homologous active regions on NEAT1 (Hb binding) and
NEAT2 (heme binding) (Supplementary Fig. 14), respectively.
The affinities of these antibodies, with dissociation constants
measured at 37 C in the low pM range in all four donors, are
beyond the proposed in vivo affinity maturation limit of 100 pM
to 1 nM (ref. 29). This perhaps results from the continuous or
intermittent exposure to very low levels of antigen as a
consequence of the commensal nature of S. aureus. Low
antigen levels may only be recognized by B cell clones
expressing these high affinity BCRs, thereby favoring their
specific stimulation and subsequent selection in the context of
the continually maturating B cell memory compartment.
We have isolated, by single-cell cloning, IGHV1-69-derived
antibodies against NEAT2 and IGHV4-39-derived antibodies
against NEAT1 from memory B cells from four donors and
additional IGHV4-39-derived antibodies against NEAT1 from
naı¨ve B cells from 13 donors using a phage display approach. We
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D16-1 IGHV4-39*07 CARPHSSSYDSLGAFDIW 1 IGKV3-20 + – –
D18-1 IGHV4-39*01 CAGIGSGSYYNPPDAFDIW 1 IGKV3-15 + – –
D28-1 IGHV4-39*01 CAGRAGSGSFDDAFDIW 0 IGKV3-20 + – –
D32-1 IGHV4-39*01 CAGLSSSSGYANDAFDIW 0 IGKV3-11 + – –
D40-1 IGHV4-39*01 CATYYGSGSGAFDIW 0 IGKV3-20 + – –
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Figure 6 | Naı¨ve IGHV4-39-derived antibodies from naı¨ve B cells. (a) Schematics of naı¨ve IGHV4-39 antibody phage library generation. CD19þ CD27
IgMþ naı¨ve B cells were isolated individually by FACS from 36 donors. Total Ig RNA was converted into cDNA using an IgM specific reverse primers, and
then uniquely barcoded IGHV4-39 primers for each donor were used to selectively amplify the IGHV4-39 VH gene from the cDNA. The amplified VH
genes were then pooled together and paired with the light chain variable genes from IGKV families 1–4 amplified from the same set of donors to generate
the single-chain Fv library. Antibody libraries were then displayed on phage and 4 rounds of panning against recombinant IsdB NEAT1 were performed.
(b) Binding characterization of IGHV4-39 encoded naı¨ve NEAT1-binding antibodies from seven different donors. Heavy and light chain germlines usage,
CDR-H3 sequence identities and number of variable heavy chain framework nucleotide mutation of the seven NEAT1 binders are shown. The observed
single framework mutation in selected clones may have been introduced by the amplification process during library generation. The binding of the parental
antibodies and their Y52A/Y53A variants to full-length IsdB was determined by SPR-based biosensor binding analysis at 37 C. The binding of the parental
antibodies to the full-length IsdB Y165R variant was determined by ELISA (n¼ 2).
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show by a combination of structural and mutagenesis data that
these antibodies bind the respective NEAT domains in a similar
fashion. The binding interaction is primarily driven by the
germline-encoded hydrophobic CDRH-2 motifs of IGHV1-69
and IGHV4-39. In fact, we also show that germline-reverted
versions of these antibodies demonstrate specific binding to their
respective NEAT domains and maintain the ability to block the
interaction with haemoglobin. Sequence analysis of the CDR3s of
the binders revealed positional preferences of certain amino acid
residues, for example a strong underrepresentation of the
canonical R at position 94 of the heavy chain for NEAT1 binders
and the presence of aromatic residues at positions 94 and 96 of
the light chain for NEAT2 binders. However, there is no
conserved residue in CDR-H3 among the binders that mediates
major contacts with the NEAT domains. Given the large size of
the human antibody repertoire30,31 and the importance of the
highly diverse CDR-H3 for binding19, antigen recognition that is
predominantly driven by the invariant V-gene encoded CDR-H2
is rarely observed. Similarly, the occurrence of multiple antibodies
isolated from different individuals that bind the same epitope
with a similar mechanism is very rare and suggests a
predetermined structural bias in the immune repertoire. Several
examples have been reported in the literature to suggest a
germline preference for antibody binding to certain antigens32,33.
One noteworthy example is the recognition of the I/i antigen
(N-acetyllactosamine) on red blood cells by IGHV4-34-derived
IgM antibodies34,35. In absence of a co-crystal structure,
mutagenesis studies suggested an unconventional binding mode
as the germline-restricted interaction with the antigen is mediated
by framework 1 residues and the C-terminal region of CDR-H3
(refs 36,37). Another example of germline-restricted response is
represented by antibodies against the capsular polysaccharide of
Haemophilus influenzae type b. A strong preference for VH3
families usage was identified, in particular IGHV3-23 and
IGHV3-15 (refs 38,39). A subset of these antibodies has a
binding interface characterized by IGHV3-23 with short CDR-H3
and IGKV2D-29 with an R residues inserted in the V–J
junction39,40. A structural model and limited mutagenesis
suggested potential interactions from all CDRs with the short
CDR-H3 and long CDR-L1 forming the floor of a groove flanked
by CDR1s and CDR2s of the heavy and light chain41. In both
cases, in the absence of definitive structural characterization,
the binding modes appear to be clearly different from the
CDR-H2-driven interaction described in our study.
Detailed structural analysis of the binding mechanism is
needed to illustrate the fine details of these germline-restricted
recognitions; however, such structural data has largely not been
available. The most prominent published body of work with
detailed structural information is represented by two sets of
IGHV1-69-derived broadly neutralizing antibodies that bind two
distinct sites on the hemagglutinin molecule (HA) of the
influenza virus. The first set of antibodies targets the receptor
binding site on the globular head of HA42,43 (Supplementary
Fig. 20) while the second set binds a structurally conserved
epitope on the stem region of the molecule44–46 (Supplementary
Fig. 21). Four antibodies from different donors that target the
receptor binding site of HA, all with a heavy chain derived from
IGHV1-69, were shown to recognize an overlapping epitope on the
head of the molecule. This led to the suggestion of a IGHV1-69
germline preference for binding this region of HA. However, the
structural data clearly shows that their binding modes are quite
different from each other (Supplementary Fig. 20). This seems to
stem from the fact that the binding interaction and orientation is
driven by the different CDR-H3s of the different antibodies.
For the antibodies targeting the stem region of HA, IGHV1-69-
derived antibodies isolated from three different donors were
shown to consistently use a signature motif on CDR-H2
(I53/M53 and F54) and Y98 from CDR-H3 to target the same
hydrophobic groove on HA47,48. Previous work has also shown
that germline-reverted versions of these broadly neutralizing
antibodies were able to engage HA49, suggesting that the
IGHV1-69 CDR-H2 motif is well suited to recognize a specific
epitope on the HA stem50. Our results parallel the work on
antibodies against the stem region of HA and show that the
germline-encoded structural motif on IGHV1-69 CDR-H2 is not
only well suited to bind the hydrophobic heme pocket of IsdB
NEAT2 of S. aureus, but is also the essential determinant of this
binding (Figs 2d and 3b). Unlike the IGHV1-69-HA-stem
binding mechanism, our data shows that CDR-H2 is so crucial
for binding that IGHV1-69-derived antibodies from different
healthy donors exhibit a nearly identical binding mechanism to
NEAT2 (Supplementary Fig. 21). Moreover, to our knowledge,
our work illustrates for the first time that the IGHV4-39 CDR-H2
motif is also particularly well suited to recognize the
haemoglobin-binding domain of IsdB NEAT1, uncovering
another example of a germline specialized in binding to a
common antigen. Altogether, the fact that both sets of antibodies
were found in all four donors tested and the results showing
that the germline-reverted version of these antibodies maintain
surprisingly high affinity for IsdB, further support the conclusion
that the CDR-H2 motifs of IGHV1-69 and IGHV4-39 represent a
particularly good fit to bind and neutralize the active sites on
NEAT1 and NEAT2 of S. aureus, respectively. Because of the high
degree of sequence identity among IsdB molecules encoded by S.
aureus strains, we expect these antibodies to be broadly
neutralizing across these strains. In addition, NEAT domains
are structurally conserved with many homologues encoded in the
genomes of Gram-positive bacteria in the phylum Firmicutes10
(Supplementary Fig. 22), therefore we speculate that IGHV1-69 and
IGHV4-39 antibodies against other significant human pathogens
such as Bacillus anthracis, Streptococcus pyogenes, Clostridium
perfringens and Listeria monocytogenes may be already present in
humans, or may be induced on antigen exposure.
Overall, our study reveals that two human germlines,
IGHV1-69 and IGHV4-39, have inherent affinity against the
specific folds of structurally conserved NEAT domains of a
bacterial commensal pathogen. The results expand the concept of
germline-restricted usage of antibodies suggested mostly for viral
pathogens50–52 and extend this to a bacterial pathogenic protein.
In addition, our work also illustrates for the first time how
germline V-gene encoded residues can be so dominant in driving
antibody binding that resulting antibodies from different
individuals exhibit nearly identical binding mechanism. The
data suggest that existing human V-genes may represent not only
V(D)J recombination scaffolds for the antibodies of the adaptive
repertoire, but also innate-like proto-receptor scaffolds to
recognize certain unique structural motifs presented by
infectious pathogens, such as the influenza virus and S. aureus.
This may allow a proportion of the adaptive immune repertoire
to activate rapidly and provide protection against a pathogen
at the earliest encounter, without the time required for
lengthy affinity maturation. Given the presumptive evolutionary
advantage of these responses53, it is possible that pathogens to
which humans are exposed seasonally or recurrently due to a
commensal relationship may have exerted evolutionary pressure
to promote the retention or expansion of specific V-gene
segments in the human repertoires.
Methods
Isolation and clustering of anti-IsdB antibodies. Blood samples of
50–100ml were collected from healthy consented donors. Drawing of blood
samples was approved by the Pfizer Institutional Review Board. The blood sample
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was first diluted 1:1 with PBS/2% FBS/1mM EDTA and centrifuged at 120g for
10min with the brake off. The plasma fraction was removed and replaced with an
equivalent volume of PBS/2% FBS/1mM EDTA. The sample was further diluted
1:1 with PBS/2% FBS/1mM EDTA and layered on top of Ficoll-Paque PLUS (GE
Healthcare). After centrifugation at 2,000 r.p.m. for 20min with brake off, PBMC
were collected from the interface and washed twice with PBS/2% FBS/1mM EDTA.
ACK lysis buffer (Thermo Fisher Scientific) was added to remove the red blood
cells. After washing the cells with PBS/2% FBS/1mM EDTA, B cells from the
PBMC were enriched using EasySep Human Pan-B Cell Enrichment kit (Stemcell
Technologies) according to the manufacturer’s protocol. After the enrichment, B
cells were washed with PBS/2% FBS/1mM EDTA and labelled at 8 C for 2–4 h
with anti-human CD3-PerCP/Cy5.5 (1:20 dilution, UCHT1), anti-human CD16
PerCP/Cy5.5 (1:20 dilution, 3G8), anti-human CD19-AlexaFluor488 (1:20
dilution, HIB19), anti-human IgM-Phycoerythrin (1:20 dilution, MHM-88),
anti-human CD27-Allophycocyanin (1:20 dilution, O323), 7-AAD (1:100 dilution)
(all from Biolegend) and 40 nM recombinant IsdB conjugated to Pacific-blue
according to the manufacturer’s protocol (Thermo Fisher Scientific). Cells were
then pelleted, washed and resuspended in PBS/2% FBS for FACS sorting. CD3 ,
CD16 , 7AAD , IgM , CD19þ , CD27þ , IsdBþ memory B cells were either
bulk sorted for high-throughput sequencing or single-cell sorted into 96-well PCR
plates for cloning. Individual cells were collected into each well of a 96-well plate
containing 3.5 ml of Quick extraction buffer (Epicenter Bio) and immediately frozen
over dry ice. Reverse transcription mixture containing 0.5 ml of reverse transcrip-
tion primers mix (Supplementary Table 1), 5 ml of 2x reaction buffer and 1 ml
of enzyme mix from SuperScript III One-Step RT-PCR system (Thermo Fisher
Scientific) was added to the cell solution and reverse transcription was carried out
at 55 C for 30min. Then, 20ml of PCR mixture containing 0.15 mM each of the
leader region primer mix, 0.25 mM each of constant reverse primer mix
(Supplementary Table 1), 10 ml of the 2 reaction buffer and 0.5 ml of enzyme mix
from the SuperScript III One-Step RT-PCR system were added directly to the tube,
which contained 10 ml of the reverse transcription reaction product. PCR reaction
conditions were 94 C for 2min, 40 cycles of 94 C for 15 s, 55 C for 30 s and 68 C
for 1min, a final extension step of 68 C for 5min. Separate nested PCR reactions
were then performed to further amplify the transcripts of heavy chain and light
chain (Vkappaþ Vlambda) using Taq polymerase system (Thermo Fisher
Scientific) according to the manufacturer’s protocol. Specifically, 0.2 mM each of
variable region forward primer mix and 0.3 mM each of constant region reverse
primer mix (Supplementary Table 1), and 2 ml of the first PCR reaction product as
template were used in the nested PCR. Reaction conditions were 94 C for 2min,
40 cycles of 94 C for 15 s, 56 C for 30 s and 72 C for 1min, and a final extension
step of 72 C for 10min. PCR amplicons were then gel-purified and sequenced.
DNA sequences were analysed using an in-house developed software that identifies
V-gene usage, J gene usage and CDRs identities. Antibodies (mAbs) sequences
were then further triaged through a clustering algorithm based on VH and VL gene
usages, CDR-H3 length and amino acid composition to identify unique clones and
potential cluster of sibling clones for recombinant antibody expression.
High-throughput sequencing of memory B cells. High-throughput sequencing
was performed as previously described54. In brief, total RNA was isolated from
bulk sorted CD3 , CD16 , 7AAD , IgM , CD19þ , CD27þ , IsdBþ
memory B cells (see above for labelling conditions) using RNeasy micro kit
according to the manufacturing protocol (Qiagen). RNA quality was assessed using
an Agilent Bioanalyzer. Total RNA was reverse-transcribed into cDNA using the
SMARTer RACE kit according to the manufacturing protocol (Clontech) and
cDNA was used as template for five IgG-VH and two IgA-VH PCR reactions. The
PCR reaction was carried out using a modified 50 SMARTer RACE 10 Universal
Primer Mix (UPM) (Clontech) with the Lib-L-specific adaptor (Roche) sequence
attached to the short oligo in the UPM (50- CCTATCCCCTGTGTGCCTTGGCA
GTCTCAGCTAATACGACTCACTATAGGGC-30) and a IgG or IgA isotype
specific 30 primers (IgG, 50-GGGAAGACSGATGGGCCCTTGG -TGG-30 ; IgA,
50-CAGGCAKGCGAYGACCACGTTCCCATC-30) with the Lib-L-specific adaptor
(50-CCATCTCATCCCTGCGTGTCTCCGACTCAG-30) and a six-nucleotide
barcode sequence attached at the 30 end. The reaction was carried out for 31 cycles
following the manufacturer’s recommendation. Barcoded IgG-VH (B640 base
pairs (bp)) and IgA-VH (B630 bp) transcript libraries were purified using AMPure
XP (Beckman Coulter), quantified using PicoGreen (Thermo Fisher Scientific) and
pooled at equimolar amounts. The final multiplexed library pools were subjected to
emulsion PCR and unidirectional sequencing using the GS FLX Titanium Lib-L
chemistry (Roche).
Lineage analysis of the memory B cells. Lineage analysis and the tree topology
were performed with the nucleotide sequences generated from 454 high-
throughput sequencing of the donor’s memory B cell repertoire and from the
corresponding single-cell cloning. The VDJ segments and VH CDR3 of each clone
were first identified by using VDJFasta31. Sequences were clustered into each clonal
lineage using the VDJFasta single linkage method described previously54. For tree
topology representation of the memory B cell repertoire, somatic hypermutations
and isotype in each sequence were identified by using VDJFasta. Sequences were
aligned with MUSCLE algorithm55. Identical sequences at the nucleotide level were
collapsed to a single sequence. To avoid erroneous connections due to DNA
amplification error, any less frequent clonal lineage member, which has
connectivity of 1 and is only one nucleotide different from a more frequent
neighbour, was grouped into the higher frequency neighbour. A lineage
tree topology was then generated using the nucleotide alignment, somatic
hypermutation level and isotype identity. The diagram was generated using
Cytoscape.
Expression and purification of mAbs and protein reagents. Human IgGs and
Fabs were expressed using the Expi293 system (Thermo Fisher Scientific). Human
IgGs were purified with MabSelect (GE Healthcare). Fabs were histidine tagged and
purified with Ni Sepharose Excel (GE Healthcare). Isd protein sequences used in
this study are based on that of S. aureus strain USA300. The genes of Isd proteins
were directly synthesized by GeneArt (Thermo Fisher Scientific) and cloned into
either the pET-20 or the pET-47 expression vector (Novagen). Isd proteins and
variants (truncations and point mutants) were expressed in BL21 DE3 cells
(Thermo Fisher Scientific) under the control of lac operator with an N-term
histidine tag and C-term Flag Tag. These constructs were purified with Ni
Sepharose Excel (GE Healthcare). The NEAT1 and NEAT2 domains utilized in
crystallization were expressed with an N-terminal histidine tag followed by a HRV
3C site using the pET-47b vector (Novagen). The NEAT domains were purified
with Ni Sepharose Excel, and then subjected to HRV 3C cleavage overnight at 4 C
for tag removal. Digested protein was then reapplied to Ni Sepharose Excel and the
flow through was collected, removing the tag and undigested protein. NEAT
domains were then complexed with their respective Fab (excess NEAT) and
underwent size exclusion chromatography using a Superdex 200 column in AKTA
(GE Healthcare). The sandwich Fab was later added at a 1:1 ratio to this complex.
Human haemoglobin (Hb) was purified from fresh red blood cells obtained
from Bioreclamation LLC. Briefly, haemoglobin from cell lysates was purified by
anion exchange chromatography using Q-sepharose XL (GE healthcare), followed
by size exclusion chromatography with Superdex 200 Prep Grade in AKTA
(GE healthcare)56.
Epitope binning. Epitope binning for the anti-IsdB mAbs was carried
out as previously described17. Briefly, anti-IsdB antibodies were individually
amine-coupled as single spots onto a SensEYE G-COOH (Ssens bv) sensor chip to
generate a 96-mAb array using a continuous flow microspotter (CFM) (Wasatch
Microfluidics Inc). The printed sensor chip was then docked into an surface
plasmon resonance (SPR) imager reader (MX96, IBIS Technologies bv) to perform
interaction analysis of an analyte’s binding towards the entire array of 96
antibodies simultaneously. Epitope binning experiments were performed using a
classical sandwich assay format where each binding cycle comprised three steps;
35 nM rIsdB was injected for 3min, 20 mgml 1 antibody analyte was injected for a
further 3min, and then the surfaces were regenerated using a 30-s injection of
75mM phosphoric acid. Ninety-six mAb analytes were injected over a 96-mAb
array per unattended run. Binding data were analysed in SPRint software v. 6.15.2.1
and analysed in Wasatch Microfluidics’ binning software for heat map generation,
sorting and node plotting.
Enzyme-linked immunosorbent assay (ELISA). Recombinant Isd proteins and
their variants (purified as described above) or commercially available alpha-toxin
(Calbiochem) and SEB (Toxin Technologies) at 2 ugml 1 in PBS were coated
directly onto 96-well Maxisorp, Nunc-immunoplates (ELISA plate, Thermo
Scientific) by incubation overnight at 4 C. Alternatively, the molecules were
captured through their FLAG tag with a previously coated anti-FLAG antibody
(F1904, Sigma-Aldrich) for 2 h at RT. Following blocking with PBS/1% BSA/0.01%
Tween-20 (ELISA buffer) for one hour at RT, the plates were washed six times with
PBS/0.05% Tween-20 on an automated plate washer. Diluted human serum sam-
ples or mAbs serial dilutions in ELISA buffer where the added and incubated with
shaking for one hour at RT. Plates were washed as above and an HRP-conjugated
goat anti-human IgG (Hþ L) (Jackson Immunoresearch,
109-001-003) diluted 1:15,000 in ELISA buffer was added and incubation
continued with shaking for one hour at RT. After a final wash as above, the plates
were developed by addition of 3,30 ,5,50-Tetramethylbenzidine (TMB) peroxidase
substrate (KPL) and the colorimetric reaction was stopped by addition of 5%
phosphoric acid (Aqua Solutions). Absorption was read at 450 nm on a Spectra
MAX 340 plate reader (Molecular Devices).
Biosensor assay to determine the Hb-blocking effect of mAbs. The anti-IsdB
mAbs were tested for their ability to block the rIsdB/Hb interaction as previously
described17. Briefly, mAbs were captured at 15 mgml 1 via anti-species sensors
(10min), 32 nM rIsdB was bound (10min) followed by 1 mM Hb. Anti-species
sensors were regenerated with 75mM phosphoric acid. An isotype-matched
negative control mAb (against an irrelevant target) was used to assess any
non-specific cross-reaction of rIsdB or Hb.
Cell-based assay to determine the Hb-blocking effect of mAbs. The binding of
human Hb to endogenously-expressed IsdB on S. aureus cells was used to assess
the blocking effect of anti-IsdB mAbs as previously described57 with the following
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modifications. The S. aureus DSpA strain was used. The antibodies, at a
concentration of 600 nM, were pre-incubated with S. aureus cells for 10min at
room temperature before purified human Hb was added to give a final Hb
concentration of 150 nM. Final detection of Hb was performed by standard
Western blotting with a biotinylated primary antibody (sheep polyclonal anti-Hb,
biotinylated, Abcam ab95152, used at 2 mgml 1) followed by a streptavidin-
conjugated secondary reagent (Streptavidin-IRDye 800 CW, 1mgml 1; Odyssey
926–32230, 1:4,000 dilution). A Licor Odyssey system was used to image the blot
and to quantify the band intensities, data were expressed as per cent of maximum
Hb binding in absence of antibodies.
Affinity measurements of anti-IsdB mAbs. Active concentrations of the
recombinant IsdB antigens were determined using a calibration-free concentration
analysis on a Biacore T200 biosensor equipped with CM5 sensor chip (GE
Healthcare), as described previously58. This assay relied on the use of a high affinity
anti-IsdB antibody that could be regenerated easily; thus D1–06 was chosen as the
reaction surface and was amine-coupled onto flow cell 2 at a high density
(8,700 RU) to promote mass transport limited binding. Flow cell 1 was left blank
(activated and blocked, without any protein coupled) to serve as a reference
surface. Surfaces were generated with 75mM phosphoric acid. These experiments
returned apparent activities of 31–34% for both the full-length recombinant IsdB
and IsdB NEAT 2 domain, and these ‘active’ concentrations were used as input
values for the kinetic experiments instead of the ‘nominal’ protein concentrations
(as determined by light absorbance at A280 nm with appropriate extinction).
Kinetic experiments were performed in a running buffer of PBS/0.01% Tween-
20 using a one-shot kinetic method59 on a ProteOn XPR36 equipped with GLC
sensor chips (BioRad). The surfaces for these experiments were prepared at 25 C.
Briefly, ligand channels were minimally activated using a 2–3 min injection of a
freshly mixed aqueous solution of 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide (EDC) and sulfo-N-hydroxysuccinimide (SNHS) at final
concentrations of 1mM EDC and 0.25mM SNHS, antibodies were amine-coupled
for 3 min at 15mgml 1 in 10mM sodium acetate pH 4.5 buffer, and excess
reactive esters were blocked with a 3min injection of 1M ethanolamine pH 8.5.
Final amine-coupled levels ranged from 400–1,000 response unit (RU) per
antibody, witho3% variation along the six spots within each ligand channel. The
temperature was then adjusted to 37 C to study the interaction of full-length
recombinant IsdB or IsdB NEAT2 domain as analytes, which were injected for
3min along the analyte channels as a five-membered serial dilution along with a
buffer sample to provide an in-line buffer blank for data processing purposes. The
dissociation phase was monitored for up to 4 h. Alternatively, the interaction
analysis was performed in a 36-ligand array format using a kinetic titration
injection methodology, as described previously60. The same surfaces were also used
to study analytes in a short and long injection methodology. The top analyte
concentration used for the kinetic experiments, regardless of the injection method
used, was adjusted as appropriate for the antibodies being studied, and varied from
active concentrations of B1 mM (for the weak affinity binders) to 20 nM (for the
high affinity binders). Analyte injections were performed in duplicate and all
experiments were repeated on different chips to generate up to three independent
measurements per interaction. Binding data were analysed using ProteOn Manager
software; the sensorgrams from the reaction spots were interspot-referenced and
double-referenced and fit globally to a simple Langmuir model with mass transport
to deduce the equilibrium dissociation constant (KD¼ kd/ka) for each rIsdB/
antibody binding interaction.
Binding of the germline-reverted antibodies were performed on a Biacore T200
SPR biosensor (GE Healthcare). Briefly, an anti-human Fc sensor chip was
prepared by activating all flow cells of a Biacore CM4 sensor chip with a 1:1 (v/v)
mixture of 400mM EDC and 100mM NHS for 7min, at a flow rate of
10ml min 1. An anti-human Fc reagent (Southern Biotech 2014-01) was diluted to
50mgml 1 in 10mM sodium acetate pH 4.5 and injected on all flow cells for 7min
at 20 ml min 1. All flow cells were blocked with 100mM ethylenediamine in
150mM Borate buffer pH 8.5 for 7min at 10 ml min 1. The running buffer for
this immobilization procedure was 10mM HEPES, 150mM NaCl, 0.05% (v/v)
Tween-20, pH 7.4. Kinetics experiments were performed at 37 C using a running
buffer of 10mM sodium phosphate, 150mM NaCl, 0.01% (v/v) Tween-20, pH 7.4.
Anti-IsdB mAbs were captured on downstream flow cells (flow cells 2, 3 and 4) at
concentrations that ranged from 8 to 20 mgml 1 at a flow rate of 10ml min 1 for
2min. Flow cell 1 was used as a blank reference surface. Following capture mAbs,
analyte (buffer, or IsdB) was injected at 30 ml min 1 on all flow cells for 2min.
Multiple IsdB analyte concentrations were tested. The IsdB analyte concentrations
were 1.6, 8.0, 40, 200 and 1,000 nM. After the analyte injection, dissociation was
monitored for 5min. Following analyte binding and dissociation all flow cells were
regenerated with three 1-minute injections of 75mM Phosphoric Acid. The
double-referenced sensorgrams were fit globally to a 1:1 Langmuir with mass
transport binding model using the Biacore T200 evaluation software.
Crystal structure determination and analysis. IsdB NEAT1 or NEAT2 in
complex with their respective Fabs were subjected to Index (Hampton Research),
JCSGþ (Qiagen) and PEG/Ion (Hampton Research) crystallization screens using
the Mosquito robot. A number of initial hits were refined using vapour diffusion
followed by microbatch using Al’s oil (Hampton Research). D2-06-N2 complex
crystallized with 20% PEG 3350 and 0.1M sodium citrate at pH 5.4. The D2-06-N2
crystal was flash frozen with liquid nitrogen using mother liquor with 20% glycerol.
D4-30-N2 complex was crystallized with 15% PEG 10K and 0.1M Tris pH 8.0, and
flash frozen with mother liquor with 20% ethylene glycol. D4-10-N1 complex
crystallized with 17% PEG 3350 and 0.2M ammonium citrate tri basic pH 7.0, and
flash frozen with mother liquor with 20% glycerol. Data collection was performed
at Advance Light Source beamline 5.0.2. (Lawrence Berkeley National Labs).
Images collected were indexed and scaled with HKL2000 (ref. 61), and Phaser62
was used for molecular replacement. The models were further refined with a
combination of Coot 0.7 (ref. 63), CCP4i 6.5.0 (ref. 64), Phenix 1.9 (ref. 65), and
autoBUSTER66.
Generation of naı¨ve IGHV4-39-derived phage antibody library. Blood samples
of 25–50ml were collected from healthy consented donors and PBMC were
isolated as described earlier. A total of 1.0–1.9 million of CD19þ (1:20 dilution,
HIB19), CD27 (1:20 dilution, O323) naı¨ve B cells were FACS isolated from the
PBMC of each donor. Total RNAs from each donor were individually obtained
using the RNeasy mini kit according to the manufacturing protocol (Qiagen). First
strand cDNA was synthesized using a human IgM heavy chain constant reverse
primer (50-GAAGGCAGCAGCACCTGTGAG-30) and a human IgK light chain
constant reverse primer (50-TGGAGGGCGTTATCCACCTTCC-30) in a reverse
transcriptase reaction (SuperscriptIII, Thermo Fisher Scientific). Light chain cDNA
from all donors were pooled and variable kappa light chain genes were amplified as
previously described using the VK family 1–4 primers and JK reverse primers67.
Heavy chain cDNA from each donor was first individually amplified for 20 cycles
using an IGHV4-39 specific leader region primer (50-TTCCTCCTGCTGGTG
GCG-30) and an IgM constant region reverse primer (50-AAGTGATGGAGTCGG
GAAGGAAG-30). PCR conditions were according to the manufacturing protocol
of Pfu Ultra (Agilent). A uniquely barcoded nesting primer for each donor was
generated by adding nine unique nucleotides combinations, which are the different
combinations of codons encoding for amino acids glycine-glycine-serine, in front
of each IGHV4-39 specific forward primer (50-CAGCTGCAGCTGCAGGA
GTC-30). The IGHV4-39 VH gene from each donor was then individually
amplified for 20 cycles using 2 ml of first PCR product as template, and the
barcoded IGHV4-39 forward primer and JH reverse primers67. Pooled VK genes
and VH genes were then sequentially ligated into a single-chain Fv antibody phage
display vector. SS320 cells (Lucigen) were transformed with the assembled scFv
library vector in thirty parallel 50 ml electroporation reactions according to the
manufacturing protocol. The size of the starting library was B6 109. Antibody-
displaying phages were recovered with M13KO7 helper phage (New England
Biolab) according to previously published methods68. Briefly, overnight phage
cultures were spun down at 12,000 g for 15min. Supernatant was collected and
incubated with 1:5 volumes of PEG 8000/2.5M NaCl (Teknova) at room
temperature for 20min. The mixture was then spun down at 15,000 g for 10min.
Supernatant was removed and PBS was added to dissolve the phage pellet.
Dissolved phage solution was spun down at 15,000 g for 10min to remove any
insoluble material. Phage supernatant was used immediately or frozen at  80 C
for storage.
Selection of NEAT1 binders from antibody phage library. For panning of phage
library, 2–4 mgml 1 of recombinant IsdB NEAT1 protein in PBS was first coated
overnight at 4 C onto 24 wells of a Maxisorp plate. Plates were then blocked with
either Superblock or StartingBlock (Thermo Fisher Scientific). After washing off
the blocking solution with PBS/0.05%Tween, 1013 phage particles (100 ml per well)
in PBS/1% BSA/0.05% Tween were then incubated with plate-bound NEAT1
protein overnight at 4 C in the first round. The amount of phage input were
subsequently reduced to 5 1012 particles in round 2, 1012 particles in round 3 and
5 1011 particles in round 4. Phage incubations for round 2 to round 4 were
performed at room temperature for 2–4 h. After phage incubation, plates were
washed with PBS/0.05%Tween for 5–20 times. Bound phages were recovered by
incubating the well with 120 ml of 100 nM HCl for 20min and immediately fol-
lowed by neutralizing with 16ml of 1M TRIS pH 9.2. The eluted phages were then
used to infect XL-1Blue (Agilent) cells growing at log phase (OD B0.3–0.6) for
phage propagation and subsequent round of panning68. After four rounds of
panning, infected E. coli were plated on LB carbenicillin plates. For screening,
single E. coli colony were picked and individually inoculated in growth media
(2YT/100 ugml 1 carbenicillin/109 M13KO7) overnight at 37 C to produce
phage. Phage cultures were then spun down and one sixth dilution of the phage
supernatant in PBS/0.5% BSA/0.05% Tween was used in ELISA to test the binding
of the phage clone to NEAT1. Phage ELISA conditions were similar to the ELISA
conditions described earlier, but anti M13-IgG-HRP conjugate (GE Healthcare,
27942101) was used as the detection reagent. Clones that were reactive to IsdB
NEAT1 and not binding negative control proteins were then sequenced. Selected
clones with unique HC sequences from different donors were reformatted as
human IgG1 for further testing.
Sequence analysis of NEAT domains of S. aureus IsdB variants. Protein
sequences from 4,152 S. aureus genomes annotated as IsdB were downloaded from
the March 2015 release of the PATRIC pathogen database69. Additional filtering
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was performed to exclude partial sequences and incorrect protein or taxonomic
classification: sequences with lengths of outside of the range 645±30 amino acids
were excluded as well as sequences from the isolates S. aureus F87619 and S. aureus
M21126. A multiple sequence alignment of the remaining 4,112 filtered protein
sequences was generated using the MUSCLE algorithm55. The alignment was
manually refined for the sequences of isolates from S. aureus subsp. aureus E1410,
S. aureus RF122 and S. aureus O11 using Jalview70. The conservation score was
computed as the frequency of the most commonly aligned residue at each position
in the alignment. The multiple sequence alignment of the representative NEAT
domain sequences was generated using the MUSCLE algorithm55 with the default
alignment parameters.
Data availability. The accession number for the structures of D2-06-N2,
D4-30-N2, and D4-10-N1 in the Protein Data Bank are 5D1Q, 5D1X and 5D1Z,
respectively.
The data that support the findings of this study are available within the article
or from the corresponding authors on request.
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